Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Stability of Blood Clotting Products Stored in Emergency Ambulances Under Real-World Conditions (STABLE-EMS)

15 de junho de 2026 atualizado por: Medical University of Graz

Stability of Human Fibrinogen (Fibryga) and Lyophilized Human Plasma (Octaplas LG AB) Under Real-World Prehospital Emergency Medical Service Storage Conditions: A Prospective Observational Study

Emergency medical service (EMS) vehicles are exposed to a wide range of environmental conditions, including high temperatures during summer months. These conditions may affect the stability and quality of medications and blood products carried for emergency treatment.

This observational study aims to evaluate the stability of human fibrinogen concentrates and human plasma proteins (Octaplas) when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. Drug samples will be analyzed monthly over a four-month period and compared with reference samples stored under recommended conditions. In addition, temperature inside the storage containers and the vehicle will be continuously monitored.

The study will assess whether prolonged exposure to real-world prehospital storage conditions affects product stability and whether any changes are associated with environmental factors. The findings may help determine whether current storage practices in EMS vehicles are adequate for maintaining the quality of these blood coagulation products.

Visão geral do estudo

Status

Ainda não está recrutando

Descrição detalhada

Emergency medical service (EMS) medications and blood products are routinely exposed to varying environmental conditions during storage and transport. Seasonal temperature fluctuations, prolonged vehicle operation, and environmental influences may result in deviations from manufacturer-recommended storage conditions. While several studies have demonstrated the stability of commonly used emergency medications under real-world prehospital conditions, limited evidence is available regarding the stability of blood coagulation products stored in EMS vehicles.

Human fibrinogen concentrates and lyophilized human plasma (Octaplas LG AB) are increasingly available in prehospital emergency care for the early management of severe hemorrhage and trauma. Both products are subject to specific storage requirements defined by the manufacturer. Although these products are intended to be stored under controlled conditions, maintaining recommended storage environments continuously in operational EMS vehicles may be challenging, particularly during periods of elevated ambient temperatures. Data regarding the impact of such environmental exposure on product stability in the prehospital setting remain scarce.

The objective of this prospective observational longitudinal study is to evaluate the stability of fibrinogen concentrates and Octaplas LG AB when stored under routine operating conditions in a ground-based EMS ambulance in Graz, Austria. The study will be conducted during the summer months from July through September 2026, representing the period with the highest expected thermal stress on medical products stored in emergency vehicles.

At study initiation, reference samples of both products will be retained under manufacturer-recommended storage conditions. Additional study samples will be placed in the ambulance medication storage system and exposed to routine operational conditions throughout the observation period. Laboratory analyses will be performed at predefined monthly intervals to assess potential changes in product stability over time. All analyses will be conducted at the Department of Blood Group Serology and Transfusion Medicine, Medical University of Graz, using validated laboratory methods appropriate for each product. Product-specific stability parameters will be compared with baseline and reference samples stored according to manufacturer recommendations.

Environmental conditions will be continuously monitored throughout the study period. Temperature sensors will be installed both within the medication storage containers and inside the ambulance vehicle. Measurements will be recorded automatically at 10-minute intervals over the entire observation period. These data will be used to characterize environmental exposure profiles and to quantify the frequency, magnitude, and duration of deviations from recommended storage conditions.

The primary objective is to determine whether storage under real-world prehospital operating conditions results in measurable changes in the stability of fibrinogen concentrates and Octaplas LG AB over a three-month observation period. Secondary objectives are to characterize temperature conditions within EMS medication storage systems, assess compliance with manufacturer-recommended storage conditions, quantify environmental excursions outside recommended storage ranges, evaluate potential associations between environmental exposure and laboratory measures of product stability, and describe seasonal storage conditions encountered in a ground-based EMS system.

No patients will be enrolled, and no clinical interventions will be performed as part of this study. The investigation is limited to pharmaceutical product samples and environmental monitoring within an operational EMS vehicle. Consequently, no patient-related outcomes, safety endpoints, adverse events, or clinical efficacy outcomes will be assessed.

Descriptive statistics will be used to summarize environmental and laboratory data. Continuous variables will be reported as means with standard deviations or medians with interquartile ranges, as appropriate. Longitudinal changes in laboratory stability parameters will be assessed across repeated measurements obtained during the observation period. Associations between environmental variables, including temperature and laboratory indicators of product stability will be explored using correlation analyses and regression-based approaches where appropriate. Missing measurements, if encountered, will not be imputed and will be reported transparently.

The results of this study are expected to provide evidence regarding the suitability of current EMS storage practices for blood coagulation products under routine operating conditions. The findings may contribute to future recommendations for the storage, transport, and quality assurance of coagulation products used in prehospital emergency medicine.

Tipo de estudo

Observacional

Inscrição (Estimado)

2

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

  • Filho
  • Adulto
  • Adulto mais velho

Aceita Voluntários Saudáveis

N/D

Método de amostragem

Amostra Não Probabilística

População do estudo

no study population

Descrição

Inclusion Criteria:

  • Fibryga samples stored in the participating ground-based EMS ambulance.
  • Octaplas LG AB samples stored in the participating ground-based EMS ambulance.
  • Samples available for laboratory analysis at the predefined study time points.
  • Samples exposed to routine operational storage conditions during the study period.

Exclusion Criteria:

  • Samples with damaged packaging.
  • Samples with incomplete storage documentation.
  • Samples accidentally removed from the designated storage system during the observation period.
  • Samples unavailable for laboratory analysis.
  • Samples exposed to conditions not representative of routine EMS operation.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

Coortes e Intervenções

Grupo / Coorte
Octaplas LG AB
Lyophilized human plasma samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.
Fibrinogen conentrate
Human fibrinogen concentrate samples stored under routine operating conditions in a ground-based EMS ambulance and analyzed longitudinally during the study period.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Stability of fibrinogen concentrates and Octaplas LG AB During Storage Under Real-World EMS Conditions
Prazo: Baseline to 3 months
Change in predefined laboratory stability parameters of fibrinogen concentrates and Octaplas LG AB after storage under routine operating conditions in a ground-based emergency medical service ambulance compared with baseline reference samples stored according to manufacturer recommendations.
Baseline to 3 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Frequency of Temperature Excursions Outside Recommended Storage Conditions
Prazo: Continuously monitored from baseline to 3 months
Number and duration of temperature measurements exceeding manufacturer-recommended storage limits for Fibryga and Octaplas LG AB during the observation period.
Continuously monitored from baseline to 3 months
Maximum and Minimum Storage Temperatures
Prazo: Baseline to 3 months
Highest and lowest temperatures recorded within medication storage compartments and inside the ambulance vehicle during the study period.
Baseline to 3 months
Compliance With Manufacturer-Recommended Storage Conditions
Prazo: Continuously monitored from baseline to 3 months
Percentage of recorded measurements within the recommended storage conditions specified by the manufacturers of Fibryga and Octaplas LG AB.
Continuously monitored from baseline to 3 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de julho de 2026

Conclusão Primária (Estimado)

30 de setembro de 2026

Conclusão do estudo (Estimado)

30 de novembro de 2026

Datas de inscrição no estudo

Enviado pela primeira vez

9 de junho de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

9 de junho de 2026

Primeira postagem (Real)

15 de junho de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de junho de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

15 de junho de 2026

Última verificação

1 de junho de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • MUG-STABLEEMS-2026-01

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever